Toxicity Studies of DOX~DEX~Fe3O4@ZIF~ Peptides in Vitro and in Vivo

Research Article
Open access

Toxicity Studies of DOX~DEX~Fe3O4@ZIF~ Peptides in Vitro and in Vivo

Meiqi Wang 1*
  • 1 Changchun University of Technology, No. 7186 Satellite Road, Nanhu Street, Chaoyang District, Changchun City, Jilin Province, China    
  • *corresponding author meiqiwang8129@gmail.com
Published on 28 April 2023 | https://doi.org/10.54254/2753-8818/4/20220664
TNS Vol.4
ISSN (Print): 2753-8826
ISSN (Online): 2753-8818
ISBN (Print): 978-1-915371-27-0
ISBN (Online): 978-1-915371-28-7

Abstract

Colorectal cancer is formed and developed through a multi-factor and multi-stage complex pathological process. The review provides an overview of the available colorectal cancer treatments and makes the case for the need to develop specific colon cancer therapeutic products that are safe and stable, with significant therapeutic efficacy and minimal patient sacrifice. The author reviews the progress made in the field of miRNA, nanomedicine system, epidermal growth factor receptor (EGFR), doxorubicin (DOX), dexmedetomidine (DEX) and peptides in the treatment of cancer and point out that more and more researchers are focusing on the treatment of cancer at the genetic level and on the combination of multiple approaches to treat cancer. This review provides an important theoretical reference for the development of multifunctional drugs for the multi-treatment targeting of colorectal cancer.

Keywords:

colorectal cancer, drug development, cancer, treatment

Wang,M. (2023). Toxicity Studies of DOX~DEX~Fe3O4@ZIF~ Peptides in Vitro and in Vivo. Theoretical and Natural Science,4,605-610.
Export citation

References

[1]. Kager L, Tamamyan G, Bielack S. Novel insights and therapeutic interventions for pediatric osteosarcoma[J]. Future Oncol., 2017, 13(4):357-368

[2]. Wang Kaiyuan, Gan Yaling, Zhou Yan, Zheng Li, Xu Jing, Liang Xingjie. Research on nano-scale and clinical translation of colorectal cancer therapeutic drugs[J]. Advances in Pharmacy, 2017,41(11):824-829

[3]. Lazarev Stanislav, Kushner Brian H, Wolden Suzanne L. Short Hypofractionated Radiation Therapy in Palliation of Pediatric Malignancies: Outcomes and Toxicities. [J]. Int. J. Radiat. Oncol. Biol. Phys., 2018,102(5):1457-1464

[4]. Harrison Douglas J, Geller David S, Gill Jonathan D, et al. Current and future therapeutic approaches for osteosarcoma.[J]. Expert Rev Anticancer Ther, 2018, 18(1): 39-50

[5]. Lu Tao, Wang Shuai, Jiang Wei. Research on small activating RNA in tumors [J]. Cancer, 2019(1): 61-66

[6]. Magalhães Mariana,Almeida Mauro, Tavares-da-Silva Elisiário,et al.miR-145-loaded micelleplexes as a novel therapeutic strategy to inhibit proliferation and migration of osteosarcoma cells.[J]. Eur. J. Pharm. Sci., 2018, 123: 28-42

[7]. Yichun Yang, Lei Han, Zewei He, et al. Advances in limb salvage treatment of osteosarcoma.[J]. Journal of Bone Oncology, 2018, 10:36-40

[8]. Chetan Nehate, M.R. Aji Alex, Arun Kumar, et al. Combinatorial delivery of superparamagnetic iron oxide nanoparticles (γFe2O3) and doxorubicin using folate conjugated redox sensitive multiblock polymeric nanocarriers for enhancing the chemotherapeutic efficacy in cancer cells.[J]. Materials Science & Engineering C, 2017, 75: 1128-1143

[9]. Pan Su, Xing Hongcun, Fu Xuqi, et al. The Effect of Photothermal Therapy on Osteosarcoma With Polyacrylic Acid-Coated Gold Nanorods.[J]. Dose Response,2018,16(3):155-158

[10]. Tiwari Arjun Prasad, Bhattarai Deval Prasad, Maharjan Bikendra, et al. Polydopamine-based Implantable Multifunctional Nanocarpet for Highly Efficient Photothermal-chemo Therapy.[J]. Sci. Rep., 2019, 9: 2943-2956

[11]. Liu Gaiwei, Dai Guo, Guo Weichun. Research progress on the role of miRNA in osteosarcoma [J]. Clinical and Experimental Medicine, 2017, 16(09): 929-932

[12]. Wang Tingting, Chen Gang, Ma Xuemei, et al. MiR-30a regulates cancer cell response to chemotherapy through SNAI1/IRS1/AKT pathway.[J]. Cell Death Dis., 2019, 10(3): 153-168

[13]. Li Yu-Sheng, Liu Qing, Tian Jian, et al. Angiogenesis Process in Osteosarcoma: An Updated Perspective of Pathophysiologyand Therapeutics.[J].Am.J.Med.Sci.,2018,357(4):280-288

[14]. Otoukesh Babak, Boddouhi Bahram, Moghtadaei Mehdi, et al. Novel molecular insights and new therapeutic strategies in osteosarcoma.[J]. Cancer Cell Int., 2018, 18(06) :158-166

[15]. Liang Lizhong, Zhang Tonghan, You Yingying, et al. An individual patient data meta-analysis on the effect of chemotherapy on survival in patients with craniofacial osteosarcoma.[J]. Head Neck, 2019;41(6):2016-2023

[16]. Xiuxia He, Fuyao Liu, Liang Liu, et al. Lectin-Conjugated Fe2O3@Au Core@Shell Nanoparticles as Dual Mode Contrast Agents for in Vivo Detection of Tumor. [J].Mol. Pharmaceutics. 2014, 11(3), 738−745

[17]. Wu S, Yang X, Luo F, Wu T, Xu P, Zou M, Yan J. Biosynthesis of flower-shaped Au nanoclusters with EGCG and their application for drug delivery. J Nanobiotechnology. 2018,16(1):90-104

[18]. Wang Xiaodan.Study of preparation and drug release of doxorubicin/curcumin degradable drug delivery system [D]. Harbin Engineering University, 2018.

[19]. Fan X,Yuan Z,Shou C,Fan G,Wang H,Gao F,Rui Y,Xu K,YinP.cRGD-Conjugated Fe3O4@PDA-DOX Multifunctional Nanocomposites for MRI and Antitumor Chemo-Photothermal Therapy. Int J Nanomedicine. 2019,14:9631-9645.

[20]. Chen Yongan,Cheng Lei,Yu Dan,Shen Jie,Zhou Zhengrong,He Shengli. Preparation of Epidermal Growth Factor-Modified Targeted Doxorubicin Nanoliposomes and Therapy of Liver Cancer.[J]. Journal of nanoscience and nanotechnology,2021,21(9):4565-4572

[21]. Chanphai P, Thomas TJ, Tajmir-Riahi HA. Application and biomolecular study of functionalized folic acid-dendrimer nanoparticles in drug delivery. [J] Biomol Struct Dyn. 2021 Feb;39(3):787-794

[22]. Xia Bing. Application of photothermal nanomaterials in cancer therapy [J]. New Chemical Materials, 2018, 46(12): 242-246

[23]. XIA M, JI N N, DUAN M L, et al. Dexmedetomidine regulate the malignancy of breast cancer cells by activating alpha 2-adrenoceptor/ERK signaling pathway[J]. Eur Rev Med Pharmacol Sci, 2016, 20(16): 3500-3506.

[24]. ]DONG W, CHEN M H, YANG Y H, et al. The effect of dexmedetomidine on expressions of inflammatory factors in patients with radical resection of gastric cancer[J]. Eur Rev Med Pharmacol Sci, 2017, 21(15): 3510-3515

[25]. Zhang Xiaomei, Zhou Yuhong, Fang Zhizhong. Application research in clinical application of folic acid [J]. Tianjin Pharmacy, 2018, 30(03): 65-69.

[26]. Zheng Zheng. Antitumor effect of cell-penetrating peptide-coupled mutant nuclear factor κB inhibitor (NFKBIA) in colorectal cancer [D]. Southern Medical University, 2020

[27]. Li Juan, Liu Guirong, Qin Haocheng, Wu Jun. Preparation of RGD targeting peptide-loaded paclitaxel polymer ultrasound contrast agent and evaluation of its targeting ability and anti-tumor effect on breast cancer cells [J]. Shandong Medicine, 2021, 61(17):5-8


Cite this article

Wang,M. (2023). Toxicity Studies of DOX~DEX~Fe3O4@ZIF~ Peptides in Vitro and in Vivo. Theoretical and Natural Science,4,605-610.

Data availability

The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.

Disclaimer/Publisher's Note

The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of EWA Publishing and/or the editor(s). EWA Publishing and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

About volume

Volume title: Proceedings of the 2nd International Conference on Biological Engineering and Medical Science (ICBioMed 2022), Part II

ISBN:978-1-915371-27-0(Print) / 978-1-915371-28-7(Online)
Editor:Gary Royle, Steven M. Lipkin
Conference website: http://www.icbiomed.org
Conference date: 7 November 2022
Series: Theoretical and Natural Science
Volume number: Vol.4
ISSN:2753-8818(Print) / 2753-8826(Online)

© 2024 by the author(s). Licensee EWA Publishing, Oxford, UK. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license. Authors who publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See Open access policy for details).

References

[1]. Kager L, Tamamyan G, Bielack S. Novel insights and therapeutic interventions for pediatric osteosarcoma[J]. Future Oncol., 2017, 13(4):357-368

[2]. Wang Kaiyuan, Gan Yaling, Zhou Yan, Zheng Li, Xu Jing, Liang Xingjie. Research on nano-scale and clinical translation of colorectal cancer therapeutic drugs[J]. Advances in Pharmacy, 2017,41(11):824-829

[3]. Lazarev Stanislav, Kushner Brian H, Wolden Suzanne L. Short Hypofractionated Radiation Therapy in Palliation of Pediatric Malignancies: Outcomes and Toxicities. [J]. Int. J. Radiat. Oncol. Biol. Phys., 2018,102(5):1457-1464

[4]. Harrison Douglas J, Geller David S, Gill Jonathan D, et al. Current and future therapeutic approaches for osteosarcoma.[J]. Expert Rev Anticancer Ther, 2018, 18(1): 39-50

[5]. Lu Tao, Wang Shuai, Jiang Wei. Research on small activating RNA in tumors [J]. Cancer, 2019(1): 61-66

[6]. Magalhães Mariana,Almeida Mauro, Tavares-da-Silva Elisiário,et al.miR-145-loaded micelleplexes as a novel therapeutic strategy to inhibit proliferation and migration of osteosarcoma cells.[J]. Eur. J. Pharm. Sci., 2018, 123: 28-42

[7]. Yichun Yang, Lei Han, Zewei He, et al. Advances in limb salvage treatment of osteosarcoma.[J]. Journal of Bone Oncology, 2018, 10:36-40

[8]. Chetan Nehate, M.R. Aji Alex, Arun Kumar, et al. Combinatorial delivery of superparamagnetic iron oxide nanoparticles (γFe2O3) and doxorubicin using folate conjugated redox sensitive multiblock polymeric nanocarriers for enhancing the chemotherapeutic efficacy in cancer cells.[J]. Materials Science & Engineering C, 2017, 75: 1128-1143

[9]. Pan Su, Xing Hongcun, Fu Xuqi, et al. The Effect of Photothermal Therapy on Osteosarcoma With Polyacrylic Acid-Coated Gold Nanorods.[J]. Dose Response,2018,16(3):155-158

[10]. Tiwari Arjun Prasad, Bhattarai Deval Prasad, Maharjan Bikendra, et al. Polydopamine-based Implantable Multifunctional Nanocarpet for Highly Efficient Photothermal-chemo Therapy.[J]. Sci. Rep., 2019, 9: 2943-2956

[11]. Liu Gaiwei, Dai Guo, Guo Weichun. Research progress on the role of miRNA in osteosarcoma [J]. Clinical and Experimental Medicine, 2017, 16(09): 929-932

[12]. Wang Tingting, Chen Gang, Ma Xuemei, et al. MiR-30a regulates cancer cell response to chemotherapy through SNAI1/IRS1/AKT pathway.[J]. Cell Death Dis., 2019, 10(3): 153-168

[13]. Li Yu-Sheng, Liu Qing, Tian Jian, et al. Angiogenesis Process in Osteosarcoma: An Updated Perspective of Pathophysiologyand Therapeutics.[J].Am.J.Med.Sci.,2018,357(4):280-288

[14]. Otoukesh Babak, Boddouhi Bahram, Moghtadaei Mehdi, et al. Novel molecular insights and new therapeutic strategies in osteosarcoma.[J]. Cancer Cell Int., 2018, 18(06) :158-166

[15]. Liang Lizhong, Zhang Tonghan, You Yingying, et al. An individual patient data meta-analysis on the effect of chemotherapy on survival in patients with craniofacial osteosarcoma.[J]. Head Neck, 2019;41(6):2016-2023

[16]. Xiuxia He, Fuyao Liu, Liang Liu, et al. Lectin-Conjugated Fe2O3@Au Core@Shell Nanoparticles as Dual Mode Contrast Agents for in Vivo Detection of Tumor. [J].Mol. Pharmaceutics. 2014, 11(3), 738−745

[17]. Wu S, Yang X, Luo F, Wu T, Xu P, Zou M, Yan J. Biosynthesis of flower-shaped Au nanoclusters with EGCG and their application for drug delivery. J Nanobiotechnology. 2018,16(1):90-104

[18]. Wang Xiaodan.Study of preparation and drug release of doxorubicin/curcumin degradable drug delivery system [D]. Harbin Engineering University, 2018.

[19]. Fan X,Yuan Z,Shou C,Fan G,Wang H,Gao F,Rui Y,Xu K,YinP.cRGD-Conjugated Fe3O4@PDA-DOX Multifunctional Nanocomposites for MRI and Antitumor Chemo-Photothermal Therapy. Int J Nanomedicine. 2019,14:9631-9645.

[20]. Chen Yongan,Cheng Lei,Yu Dan,Shen Jie,Zhou Zhengrong,He Shengli. Preparation of Epidermal Growth Factor-Modified Targeted Doxorubicin Nanoliposomes and Therapy of Liver Cancer.[J]. Journal of nanoscience and nanotechnology,2021,21(9):4565-4572

[21]. Chanphai P, Thomas TJ, Tajmir-Riahi HA. Application and biomolecular study of functionalized folic acid-dendrimer nanoparticles in drug delivery. [J] Biomol Struct Dyn. 2021 Feb;39(3):787-794

[22]. Xia Bing. Application of photothermal nanomaterials in cancer therapy [J]. New Chemical Materials, 2018, 46(12): 242-246

[23]. XIA M, JI N N, DUAN M L, et al. Dexmedetomidine regulate the malignancy of breast cancer cells by activating alpha 2-adrenoceptor/ERK signaling pathway[J]. Eur Rev Med Pharmacol Sci, 2016, 20(16): 3500-3506.

[24]. ]DONG W, CHEN M H, YANG Y H, et al. The effect of dexmedetomidine on expressions of inflammatory factors in patients with radical resection of gastric cancer[J]. Eur Rev Med Pharmacol Sci, 2017, 21(15): 3510-3515

[25]. Zhang Xiaomei, Zhou Yuhong, Fang Zhizhong. Application research in clinical application of folic acid [J]. Tianjin Pharmacy, 2018, 30(03): 65-69.

[26]. Zheng Zheng. Antitumor effect of cell-penetrating peptide-coupled mutant nuclear factor κB inhibitor (NFKBIA) in colorectal cancer [D]. Southern Medical University, 2020

[27]. Li Juan, Liu Guirong, Qin Haocheng, Wu Jun. Preparation of RGD targeting peptide-loaded paclitaxel polymer ultrasound contrast agent and evaluation of its targeting ability and anti-tumor effect on breast cancer cells [J]. Shandong Medicine, 2021, 61(17):5-8